GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Cyclically Adjusted FCF per Share

Intra-Cellular Therapies (STU:23I) Cyclically Adjusted FCF per Share : €-2.50 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Intra-Cellular Therapies Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Intra-Cellular Therapies's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.324. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.50 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-09), Intra-Cellular Therapies's current stock price is €62.50. Intra-Cellular Therapies's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-2.50. Intra-Cellular Therapies's Cyclically Adjusted Price-to-FCF of today is .


Intra-Cellular Therapies Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Intra-Cellular Therapies's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Cyclically Adjusted FCF per Share Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -2.55 -2.40

Intra-Cellular Therapies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.68 -2.49 -2.66 -2.40 -2.50

Competitive Comparison of Intra-Cellular Therapies's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Cyclically Adjusted Price-to-FCF falls into.



Intra-Cellular Therapies Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intra-Cellular Therapies's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.324/131.7762*131.7762
=-0.324

Current CPI (Mar. 2024) = 131.7762.

Intra-Cellular Therapies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.131 100.560 -0.172
201409 -0.117 100.428 -0.154
201412 -0.171 99.070 -0.227
201503 -0.487 99.621 -0.644
201506 -0.794 100.684 -1.039
201509 -0.520 100.392 -0.683
201512 -0.747 99.792 -0.986
201603 -0.409 100.470 -0.536
201606 -0.279 101.688 -0.362
201609 -0.611 101.861 -0.790
201612 -0.623 101.863 -0.806
201703 -0.354 102.862 -0.454
201706 -0.512 103.349 -0.653
201709 -0.280 104.136 -0.354
201712 -0.392 104.011 -0.497
201803 -0.405 105.290 -0.507
201806 -0.526 106.317 -0.652
201809 -0.445 106.507 -0.551
201812 -0.469 105.998 -0.583
201903 -0.573 107.251 -0.704
201906 -0.455 108.070 -0.555
201909 -0.497 108.329 -0.605
201912 -0.560 108.420 -0.681
202003 -0.712 108.902 -0.862
202006 -0.629 108.767 -0.762
202009 -0.778 109.815 -0.934
202012 -0.699 109.897 -0.838
202103 -0.496 111.754 -0.585
202106 -0.606 114.631 -0.697
202109 -0.828 115.734 -0.943
202112 -0.795 117.630 -0.891
202203 -0.818 121.301 -0.889
202206 -0.952 125.017 -1.003
202209 -0.571 125.227 -0.601
202212 -0.390 125.222 -0.410
202303 -0.590 127.348 -0.611
202306 -0.354 128.729 -0.362
202309 -0.246 129.860 -0.250
202312 -0.020 129.419 -0.020
202403 -0.324 131.776 -0.324

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Intra-Cellular Therapies  (STU:23I) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Intra-Cellular Therapies Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (STU:23I) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (STU:23I) Headlines

No Headlines